Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bassand, 2007, Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes, Eur Heart J, 28, 1598, 10.1093/eurheartj/ehm161
Van de Werf, 2008, Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology, Eur Heart J, 29, 2909, 10.1093/eurheartj/ehn416
Wijns, 2010, Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), Eur Heart J, 31, 2501, 10.1093/eurheartj/ehq277
Wallentin, 2009, Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 361, 1045, 10.1056/NEJMoa0904327
Janzon, 2010, Health Economics in the PLATelet inhibition and patient Outcomes (PLATO) randomised trial: report on within trial resource use patterns, Circulation, 122, A17295
Drummond, 2005, Methods for the Economic Evaluation of Health Care Programmes, 3rd ed., 10.1093/oso/9780198529446.001.0001
James, 2009, Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial, Am Heart J, 157, 599, 10.1016/j.ahj.2009.01.003
Cannon, 2010, Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study, Lancet, 375, 283, 10.1016/S0140-6736(09)62191-7
Summary of product characteristics. Brilique: EPAR—product information
European Central Bank, Statistical Data Warehouse
Collett, 2003, Modelling Survival Data in Medical Research, 2nd ed.
Dolan, 1997, Modeling valuations for EuroQol health states, Med Care, 35, 1095, 10.1097/00005650-199711000-00002
Statistics Sweden, Lifetables during 2005–2009, for men and women
Norhammar, 2008, Women younger than 65 years with diabetes mellitus are a high-risk group after myocardial infarction: a report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA), Heart, 94, 1565, 10.1136/hrt.2007.135038
Sigvant, 2011, Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?, Eur J Cardiovasc Prev Rehabil, 18, 254, 10.1177/1741826710389368
Burström, Hälsorelaterad livskvalitet i Stockholms län 2002: resultat per åldersgrupp och kön, utbildningsnivå, födelseland samt sysselsättningsgrupp—en befolkningsundersökning med EQ-5D
Johannesson, 1993, On the decision rules of cost-effectiveness analysis, J Health Econ, 12, 459, 10.1016/0167-6296(93)90005-Y
Claxton, 2002, A rational framework for decision making by the National Institute For Clinical Excellence (NICE), Lancet, 360, 711, 10.1016/S0140-6736(02)09832-X
Fenwick, 2004, Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions, Health Econ, 13, 405, 10.1002/hec.903
Stenestrand, 2010, The Platelet Inhibition and Patient Outcomes Trial is Representative of Patients with Acute Coronary Syndromes in a National Heart Registry, J Am Coll Cardiol, 55, A112.E1046., 10.1016/S0735-1097(10)61047-9
Mahoney, 2010, Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38, Circulation, 121, 71, 10.1161/CIRCULATIONAHA.109.900704
Morrow, 2009, Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction, Circulation, 119, 2758, 10.1161/CIRCULATIONAHA.108.833665
Prasad, 2009, Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial, J Am Coll Cardiol, 54, 477, 10.1016/j.jacc.2009.03.063
Weintraub, 2005, Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation, J Am Coll Cardiol, 45, 838, 10.1016/j.jacc.2004.11.051
Mahoney, 2002, Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction, JAMA, 288, 1851, 10.1001/jama.288.15.1851
Henriksson, 2008, The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial, Heart, 94, 717, 10.1136/hrt.2007.127340
Janzon M. Treatment strategies in unstable coronary artery disease, economic and quality of life evaluations [dissertation] 2003 Linköping University 1 176 Medical dissertation No. 811
Dennis, 1993, Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project, Stroke, 24, 796, 10.1161/01.STR.24.6.796